INBRIJA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Inbrija, and when can generic versions of Inbrija launch?
Inbrija is a drug marketed by Acorda and is included in one NDA. There are ten patents protecting this drug.
This drug has one hundred patent family members in twenty-two countries.
The generic ingredient in INBRIJA is levodopa. There are eighteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the levodopa profile page.
DrugPatentWatch® Generic Entry Outlook for Inbrija
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 16, 2032. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for INBRIJA
International Patents: | 100 |
US Patents: | 10 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 119 |
Patent Applications: | 4,187 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for INBRIJA |
What excipients (inactive ingredients) are in INBRIJA? | INBRIJA excipients list |
DailyMed Link: | INBRIJA at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for INBRIJA
Generic Entry Date for INBRIJA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for INBRIJA
US Patents and Regulatory Information for INBRIJA
INBRIJA is protected by ten US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of INBRIJA is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting INBRIJA
Particulate compositions for pulmonary delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Particulate compositions for pulmonary delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Capsules containing high doses of levodopa for pulmonary use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Pulmonary delivery for levodopa
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INBRIJA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | See Plans and Pricing | See Plans and Pricing |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | See Plans and Pricing | See Plans and Pricing |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | See Plans and Pricing | See Plans and Pricing |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | See Plans and Pricing | See Plans and Pricing |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | See Plans and Pricing | See Plans and Pricing |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | See Plans and Pricing | See Plans and Pricing |
Acorda | INBRIJA | levodopa | POWDER;INHALATION | 209184-001 | Dec 21, 2018 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INBRIJA
When does loss-of-exclusivity occur for INBRIJA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13342246
Estimated Expiration: See Plans and Pricing
Patent: 13342247
Estimated Expiration: See Plans and Pricing
Patent: 13342248
Estimated Expiration: See Plans and Pricing
Patent: 17279626
Estimated Expiration: See Plans and Pricing
Patent: 18204674
Estimated Expiration: See Plans and Pricing
Patent: 18222983
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2015010601
Estimated Expiration: See Plans and Pricing
Canada
Patent: 90451
Estimated Expiration: See Plans and Pricing
Patent: 90454
Estimated Expiration: See Plans and Pricing
Patent: 90459
Estimated Expiration: See Plans and Pricing
China
Patent: 4918607
Estimated Expiration: See Plans and Pricing
Patent: 5120843
Estimated Expiration: See Plans and Pricing
Patent: 9106697
Estimated Expiration: See Plans and Pricing
Patent: 0833539
Estimated Expiration: See Plans and Pricing
Denmark
Patent: 16821
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 16821
Estimated Expiration: See Plans and Pricing
Patent: 16826
Estimated Expiration: See Plans and Pricing
Patent: 25611
Estimated Expiration: See Plans and Pricing
Patent: 15679
Estimated Expiration: See Plans and Pricing
Patent: 57301
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 12884
Estimated Expiration: See Plans and Pricing
Patent: 13186
Estimated Expiration: See Plans and Pricing
Patent: 13187
Estimated Expiration: See Plans and Pricing
Patent: 13535
Estimated Expiration: See Plans and Pricing
Patent: 14957
Estimated Expiration: See Plans and Pricing
Japan
Patent: 47786
Estimated Expiration: See Plans and Pricing
Patent: 48501
Estimated Expiration: See Plans and Pricing
Patent: 69808
Estimated Expiration: See Plans and Pricing
Patent: 21629
Estimated Expiration: See Plans and Pricing
Patent: 36834
Estimated Expiration: See Plans and Pricing
Patent: 15536197
Estimated Expiration: See Plans and Pricing
Patent: 15536988
Estimated Expiration: See Plans and Pricing
Patent: 15536989
Estimated Expiration: See Plans and Pricing
Patent: 18150355
Estimated Expiration: See Plans and Pricing
Patent: 18162258
Estimated Expiration: See Plans and Pricing
Patent: 19213867
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 1008
Estimated Expiration: See Plans and Pricing
Patent: 15005767
Estimated Expiration: See Plans and Pricing
Patent: 15005768
Estimated Expiration: See Plans and Pricing
New Zealand
Patent: 8682
Estimated Expiration: See Plans and Pricing
Patent: 8684
Estimated Expiration: See Plans and Pricing
Patent: 3459
Estimated Expiration: See Plans and Pricing
Patent: 7376
Estimated Expiration: See Plans and Pricing
Patent: 7378
Estimated Expiration: See Plans and Pricing
Poland
Patent: 16821
Estimated Expiration: See Plans and Pricing
Portugal
Patent: 16821
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 70987
Estimated Expiration: See Plans and Pricing
Patent: 76093
Estimated Expiration: See Plans and Pricing
Patent: 15121091
Estimated Expiration: See Plans and Pricing
Patent: 15121092
Estimated Expiration: See Plans and Pricing
Patent: 18144622
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 201706465X
Estimated Expiration: See Plans and Pricing
Patent: 201707103S
Estimated Expiration: See Plans and Pricing
Patent: 202109328Q
Estimated Expiration: See Plans and Pricing
Patent: 201503543P
Estimated Expiration: See Plans and Pricing
Patent: 201503547T
Estimated Expiration: See Plans and Pricing
South Africa
Patent: 1504058
Estimated Expiration: See Plans and Pricing
Patent: 1504060
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 2257164
Estimated Expiration: See Plans and Pricing
Patent: 2337781
Estimated Expiration: See Plans and Pricing
Patent: 150108816
Estimated Expiration: See Plans and Pricing
Patent: 150110480
Estimated Expiration: See Plans and Pricing
Patent: 210062730
Estimated Expiration: See Plans and Pricing
Patent: 210152020
Estimated Expiration: See Plans and Pricing
Spain
Patent: 44153
Estimated Expiration: See Plans and Pricing
Patent: 80271
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering INBRIJA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Lithuania | 2630954 | See Plans and Pricing | |
European Patent Office | 2916826 | POUDRES PULMONAIRES DE DENSITÉ ULTRA BASSE (ULTRA LOW DENSITY PULMONARY POWDERS) | See Plans and Pricing |
China | 105120843 | Ultra low density pulmonary powders | See Plans and Pricing |
Israel | 158357 | INHALATION DEVICE | See Plans and Pricing |
Israel | 153281 | See Plans and Pricing | |
Hong Kong | 1213186 | 用於肺部使用的高劑量左旋多巴膠囊 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE) | See Plans and Pricing |
Canada | 2465675 | COMPOSITIONS PARTICULAIRES AMELIOREES DESTINEES A ETRE ADMINISTREES PAR VOIE PULMONAIRE (IMPROVED PARTICULATE COMPOSITIONS FOR PULMONARY DELIVERY) | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for INBRIJA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613296 | 92782 | Luxembourg | See Plans and Pricing | PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224 |
1613296 | CR 2015 00042 | Denmark | See Plans and Pricing | PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |